<DOC>
	<DOCNO>NCT00923364</DOCNO>
	<brief_summary>Background : - Stem cell immature blood cell grow bone marrow produce cell need normal blood immunity . Stem cell take one person ( donor ) give another person ( recipient ) allogeneic stem cell transplantation . Donor stem cell replace recipient stem cell bone marrow , restore normal blood production immunity . Most allogeneic transplant use stem cell collect donor blood process call peripheral blood stem cell transplantation . - MonoMAC immunodeficiency disease characterize lack monocyte , type white blood cell , increase risk develop mycobacteria infection may cause tuberculosis . - Allogeneic stem cell transplantation use successfully treat many kind immune disease cancer develop blood immune system cell . Researchers study particular kind stem cell transplantation use low usual dos chemotherapy particular combination drug improve result procedure patient blood-related cancer pre-cancerous condition . Objectives : - To determine safety efficacy reduced-intensity hematopoietic stem cell transplant ( particular stem cell transplantation procedure ) treat MonoMAC . Eligibility : - Patients 18 60 year age MonoMAC match suitable stem cell donor . Design : - Donors recipient undergo separate procedure part protocol . - Donors : - National Institutes Health researcher take donor medical history , perform physical exam , take blood sample , explain procedure . Tests perform check donor heart , lung , kidney , liver function . - Donors receive injection drug call filgrastim ( G-CSF ) , cause stem cell travel bone marrow blood . The G-CSF shot give 5 7 day collection procedure . - Donors undergo apheresis collect white blood cell stem cell directly blood , do outpatient procedure . Researchers may consider alternative directly collect bone marrow donor , require overnight hospital stay . - Recipients : - Recipients receive 3 day pre-transplant chemotherapy radiation therapy prepare transplant . For 4 day transplant , recipient receive chemotherapy drug fludarabine , follow single dose radiation therapy , also receive drug tacrolimus sirolimus prevent donor cell attack recipient normal tissue . - Recipients receive transplant donor stem cell continue receive tacrolimus sirolimus 3 month transplant prevent donor cell attack recipient normal tissue . Recipients discharge hospital condition stable . - Recipients visit NCI clinic regularly first 5 month transplant , less often least 5 year . Recipients may receive additional donor immune cell ( donor lymphocyte infusion ) transplant study doctor believe need .</brief_summary>
	<brief_title>Pilot Feasibility Study Reduced-Intensity Hematopoietic Stem Cell Transplant MonoMAC</brief_title>
	<detailed_description>BACKGROUND : Mutations GATA2 lead immunodeficiency disease transform intomyelodysplastic syndrome ( MDS ) acute myelogenous leukemia ( AML ) . This syndrome , previously know MonoMAC , 4 clinical feature : 1 ) infection Mycobacterium Avium Complex ( MAC ) opportunistic infection teenager young adult , 2 ) peripheral blood leukocyte flow cytometry profile Tlymphocytes , severe deficiency monocyte , B-lymphocytes , Natural Killer ( NK ) cell , 3 ) propensity progress MDS/AML , 4 ) mutation gene GATA2 . In pilot study propose evaluate efficacy safety reduce intensity allogeneic hematopoietic stem cell transplantation ( HSCT ) regimen patient mutation GATA2 . We particularly interested determine whether allogeneic HSCT use regimen reconstitute normal hematopoiesis patient mutation GATA2 . OBJECTIVES : Primary Objective : - To determine efficacy , namely whether reduced-intensity allogeneic HSCT result engraftment restores normal hematopoiesis day +100 patient mutation GATA2 . - To determine safety HSCT regimen patient mutation GATA2 , include transplant related toxicity , incidence acute chronic graft-versushost disease , immune reconstitution , overall survival , disease-free survival ELIGIBILITY : Eligibility include patient 12-60 year old mutation GATA2 life expectancy &gt; 3 month &lt; 24 month , 10/10 match related donor , 10/10 9/10 match unrelated donor ( HLA -A , -B , -C , DRB1 , DQB1 high resolution type identify National Marrow Donor Program ) , 4/6 ( great HLA -A , -B , DRB1 ) match unrelated umbilical cord donor , haploidentical donor . Patients GATA2 mutation 12-17 year age require MDS chromosomal abnormality eligible protocol . DESIGN : - Patients mutation GATA2 10/10 match related 10/10 match unrelated donor , receive reduced-intensity pre-transplant conditioning regimen consist fludarabine 30 mg/m2/day day -4 , -3 , -2 , 200 cGy total body irradiation ( TBI ) day -1 , HSCT day 0 . Patients mutation GATA2 9/10 match unrelated donor receive reduced-intensity pre-transplantconditioning regimen consist fludarabine 30 mg/m2/day day -4 , -3 , -2 , 300cGy total body irradiation ( TBI ) day -1 , HSCT day 0 . Patients mutation GATA2 umbilical cord blood unit receive reduced-intensity conditioningregimen cyclophosphamide 50 mg/kg day -6 , fludarabine 40 mg/m2 day -6 -2 , equine ATG 30 mg/kg IV day -6 , -5 -4 , 200 cGy TBI day -1 , HSCT day 0 . Patients haploidentical donor receive reduce intensity-conditioning regimen cyclophosphamide 14.5 mg/kg day -6 -5 , fludarabine 30 mg/m2 4days -6 -2 , 200 cGy TBI day -1 . Donor bone marrow cell infuse day 0 . - Post-transplant immunosuppression graft-versus-host-disease prophylaxis consist sirolimus ( Rapamycin ) tacrolimus day +180 , provide evidence graft-versus-host disease . Post-transplant immunosuppression graftversus-host-disease prophylaxis recipient haploidentical donor consist cyclophosphamide 50 mg/kg day +3 +4 , along sirolimus day +5 day 180 , tacrolimus day +5 day 180 , provide GVHD .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>INCLUSION CRITERIA RECIPIENT : 1 . Patient age 1260 year 2 . GATA2 Mutation Syndrome 1 . Clinical history least two episode lifethreatening infection opportunistic organism , one MAC infection . 2 . Mutation GATA2 gene perform CLIA certify laboratory Dr. Steven Holland NIAID Institute NIH . 3 . Available 10/10 HLAmatched relate 8/8 match unrelated donor , 4/6 ( great ) match umbilical cord blood ( UCB ) unit ( ) total dose great equal 3.5 time 10 ( 7 ) TNC/kg . 4 . Patients may evidence MDS one peripheral blood cytopenia great 5 % blast le 10 % blast bone marrow absence GCSF . Patients previously treat acute myelogenous leukemia eligible less equal 10 % blast bone marrow absence GCSF . Subjects 1217 year age require MDS chromosomal abnormality addition mutation GATA2 gene enrollment protocol . 5 . Left ventricular ejection fraction &gt; 50 % , preferably 2D echo , MUGA , shorten fraction &gt; 28 % ECHO , obtain within 28 day enrollment . 6 . Pulmonary Function Tests : Adult patient : Corrected DLCO diffusion capacity FEV1 great 10 % expect value obtain within 28 day enrollment . Pediatric patient : DLCO correct hemoglobin alveolar volume great equal 20 % predict . 7 . Creatinine : Adult patient : less equal 2.0 mg/dl creatinine clearance great equal 30 ml/min ; Pediatric patient : ageadjusted normal serum creatinine OR creatinine clearance &gt; 60 mL/min/1.73m ( 2 ) . 8 . Serum total bilirubin le 2.5 mg/dl ; serum ALT AST less equal 5 time upper limit normal . 9 . Adequate central venous access potential . 10 . Written inform consent/assent obtain patient/parent legal guardian . 11 . Life expectancy least 3 month le 24 month . 12 . Disease status : Patients refer remission evaluation . Should patient progressive disease donor available enrollment , patient refer back primary hematologistoncologist treatment . If course action best interest patient accord clinical judgment PI/LAI , patient may receive standard treatment malignant disease current study . If either setting , become apparent patient able proceed transplant , he/she must come study . RecipientSubjects receive standard therapy tell therapy , associate risk , benefit alternative propose therapy , availability receive treatment elsewhere , outside research protocol . EXCLUSION CRITERIA RECIPIENT : 1 . HIV infection . 2 . Chronic active hepatitis B . Patient may hepatitis B core antibody positive . For patient concomitant positive hepatitis B surface antigen , patient require hepatology consultation . The riskbenefit profile transplant hepatitis B discuss patient , eligibility determine PI protocol chairperson . 3 . History psychiatric disorder may compromise compliance transplant protocol , allow appropriate inform consent . 4 . Active infection respond antimicrobial therapy . 5 . Active CNS involvement malignancy ( patient know positive CSF cytology parenchymal lesion visible CT MRI ) . 6 . Pregnant lactating . 7 . Sexually active individual capable become pregnant unable unwilling use effective form ( ) contraception time enrol study 1 year posttransplant . Effective form contraception include one following : intrauterine device ( IUD ) , hormonal ( birth control pill , injection , implant ) , tubal ligation/hysterectomy , partner vasectomy , barrier method , ( condom , diaphragm , cervical cap ) , abstinence . The effect breastmilk also unknown may harmful infant ; therefore , woman breast feed interval study entry one year posttransplant . Males protocol must use effective form contraception study entry , one year posttransplant . The effect transplant , radiation , medication use transplant may harmful fetus . 8 . Presence active malignancy another organ system hematopoietic 9 . No available 10/10 HLAmatched relate 8/8 match unrelated donor , 4/6 ( great ) match UCB unit ( ) total dose great equal 3.5 time 10 ( 7 ) TNC/kg . 10 . Lack mutation GATA2 demonstrate CLIA certify laboratory Dr. Steven Holland NIAID . INCLUSION CRITERIA MATCHED RELATED DONOR : 1 . Related donor match HLAA , B , C , DR , DQ loci high resolution typing ( 10/10 antigen/allele match ) acceptable donor . 2 . Matched related donor pediatric recipient must 18 year age old . If one match related donor available , select old donor decrease risk potential disease transmission . 3 . Ability give inform consent . 4 . Age 1860 year . 5 . No history lifethreatening opportunistic infection . 6 . Adequate venous access peripheral apheresis , consent use temporary central venous catheter apheresis . 7 . Donors must HIV negative , hepatitis B surface antigen negative , hepatitis C antibody negative . This prevent possible transmission infection recipient . 8 . A donor lactating must willing able interrupt breastfeed substitute formula feed infant period filgrastim administration two day follow final dose . Filgrastim may secrete human milk , although bioavailability source know . Limited clinical data suggest shortterm administration filgrastim sargramostim neonate associate adverse outcome . INCLUSION CRITERIA MATCHED UNRELATED DONOR : 1 . Unrelated donor match 10/10 9/10 HLAA , B , C , DRB1 , DQB1 loci high resolution type . 2 . Matched unrelated donor pediatric recipient must 18 year age old . 3 . The evaluation donor shall accordance exist NMDP Standard Policies Procedures . General donor inclusion criterion specify NMDP Standard . EXCLUSION CRITERIA MATCHED RELATED DONOR : 1 . Age le 18 year . 2 . HIV infection . 3 . Chronic active hepatitis B. Donor may hepatitis core antibody positive . 4 . History psychiatric disorder opinion PI may compromise compliance transplant protocol , allow appropriately inform . 5 . History hypertension control medication , stroke , severe heart disease . Individuals symptomatic angina consider severe heart disease eligible donor . 6 . Other medical contraindication stem cell donation ( i.e . severe atherosclerosis , autoimmune disease , iritis episcleritis , deep venous thrombosis , cerebrovascular accident ) . 7 . History prior malignancy . However , cancer survivor undergo potentially curative therapy may consider stem cell donation casebycase basis . The risk/benefit transplant possibility transmit viable tumor cell time transplantation discuss patient . 8 . Donors must pregnant . Pregnancy absolute contraindication protocol . The effect cytokine administration fetus unknown . Donors childbearing potential must use effective method contraception . Effective form contraception include one following : intrauterine device ( IUD ) , hormonal ( birth control pill , injection , implant ) , tubal ligation/hysterectomy , partner vasectomy , barrier method , ( condom , diaphragm , cervical cap ) , abstinence . 9 . Thrombocytopenia ( platelet le 150,000 per micro l ) baseline evaluation . 10 . Donors receive experimental therapy investigational agent . 11 . Sensitivity filgrastim E. coliderived recombinant protein product . 12 . History autoimmune disorder , exception thyroid disorder . 13 . History document deep vein thrombosis pulmonary embolism . EXCLUSION CRITERIA MATCHED UNRELATED DONOR : Failure qualify NMDP donor INCLUSION CRITERIA UMBILICAL CORD BLOOD UNITHLA TYPING AND DOSE 1 . At least HLA UCB 4/6 match ( Class IA , B low resolution , Class IIDR high resolution ) recipient . The following algorithm apply determine patient receive single double umbilical cord graft : 2 . For Single UCB SCT : If 6/6 match unit must &gt; 3 x 10 ( 7 ) nucleate cell /kg recipient body weight . If 5/6 match unit must &gt; 4 x 10 ( 7 ) nucleate cell /kg recipient body weight . If 4/6 match unit must &gt; 5 x 10 ( 7 ) nucleate cells/kg recipient body weight . Recipient body weight determine per standard guideline . 3 . If single UCB characteristic available , double UCB consider . Units select follow criterion : Both unit least 4/6 match ( Class IA , B low resolution , Class IIDR high resolution ) recipient , least 4/6 match ( Class IA , B low resolution , Class IIDR high resolution ) . At least one UCB minimum cell dose 2.0 X 10 ( 7 ) TNC/kg recipient body weight . The minimum combine dose unit must least 3.5 x 10 ( 7 ) TNC/kg recipient body weight . The small two unit ( UCB2 ) minimum 1.5 X 10 ( 7 ) TNC/kg recipient body weight . The TNC nonRBC reduce unit dose correct 25 % allow cell loss wash unit . INCLUSION CRITERIA HAPLOIDENTICAL RELATED DONOR : A haploidentical donor share one haplotype common recipient HLA compatibility minimum 5 10 HLA locus match . The HLA locus test HLA A , B , Cw , DRB1 , DQB1 . A minimum number mismatch desirable ; however several option available selection donor base loci mismatch occur relative importance potential immunological function . Donorrecipient pair initially type molecularly provide low resolution typing ( antigenlevel ) aid selection potential donor . Upon review familial inheritance pattern , qualify HLA staff member review haplotype inheritance . High resolution ( allelelevel ) typing perform . Final selection donor consultation NCI physician qualify HLA personnel . Haploidentical related donor pediatric recipient must 15 year age old . If one haploidentical relate donor available , evaluate donor individually accord overall health , ABO matching , CMV , etc . select donor Age 1560 year No history lifethreatening opportunistic infection Adequate venous access peripheral apheresis , consent use temporary central venous catheter apheresis . Donors must HIV negative , hepatitis B surface antigen negative , hepatitis C antibody negative . This prevent possible transmission infection recipient . Haploidentical donor undergo marrow harvest general anesthesia . Subjects undergo anesthesia consultation , meet criterion eligibility/enrollment . CD34+ fraction determine . Subjects also undergo Donor Health History Screen determine donor eligibility use standard DTM criterion Dowling Apheresis Clinic skilled staff Blood Services Section adult patient ageappropriate question indicate pediatric subject . Subjects undergo followup history physical examination within 1 week donation . EXCLUSION CRITERIA HAPLOIDENTICAL DONOR : Age le 15 year . HIV infection Chronic active hepatitis B. Donor may hepatitis core antibody positive . History psychiatric disorder opinion PI may compromise compliance transplant protocol , allow appropriate informed History hypertension control medication , stroke , severe heart disease . Individuals symptomatic angina consider severe heart disease eligible donor . Other medical contraindication stem cell donation ( i.e . severe atherosclerosis , autoimmune disease , iritis episcleritis , deep venous thrombosis , cerebrovascular accident ) History prior malignancy . However , cancer survivor undergo potentially curative therapy may consider stem cell donation casebycase basis . The risk/benefit transplant possibility transmit viable tumor cell time transplantation discuss patient . Donors must pregnant . Pregnancy absolute contraindication protocol . The effect cytokine administration fetus unknown . Donors childbearing potential must use effective method contraception . Effective form contraception include one following : intrauterine device ( IUD ) , hormonal ( birth control pill , injection , implant ) , tubal ligation/hysterectomy , partner vasectomy , barrier method , ( condom , diaphragm , cervical cap ) , abstinence . Thrombocytopenia ( platelet le 150,000 per microliter ) baseline evaluation . Donors receive experimental therapy investigational agent . Sensitivity filgrastim E. coliderived recombinant protein product . History autoimmune disorder , exception thyroid disorder History document deep vein thrombosis pulmonary embolism Mutation GATA2</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 23, 2016</verification_date>
	<keyword>GATA2</keyword>
	<keyword>Transplant</keyword>
	<keyword>Immunodeficiency</keyword>
	<keyword>Myelodysplasia</keyword>
	<keyword>MonoMAC</keyword>
</DOC>